| Year |
Citation |
Score |
| 2020 |
Mukhtar E, Worroll D, Galletti G, Schuster S, Piha-Paul SA, Giannakakou P. Quantitative analysis of taxane drug target engagement of microtubules in circulating tumor cells from metastatic castration resistant prostate cancer patients treated with CRXL301, a nanoparticle of docetaxel. Cancer Drug Resistance (Alhambra, Calif.). 3: 636-646. PMID 33062959 DOI: 10.20517/cdr.2019.116 |
0.334 |
|
| 2020 |
Shah MA, Enzinger P, Ko AH, Ocean AJ, Philip PA, Thakkar PV, Cleveland K, Lu Y, Kortmansky J, Christos PJ, Zhang C, Kaur N, Elmonshed D, Galletti G, Sarkar S, ... ... Giannakakou P, et al. Multicenter phase II study of Cabazitaxel in advanced gastroesophageal cancer: Association of HER2 Expression and M2-like Tumor Associated Macrophages with Patient Outcome. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 32641434 DOI: 10.1158/1078-0432.Ccr-19-3920 |
0.317 |
|
| 2020 |
Gjyrezi A, Xie F, Voznesensky O, Khanna P, Calagua C, Bai Y, Kung J, Wu J, Corey E, Montgomery B, Mace S, Gianolio DA, Bubley GJ, Balk SP, Giannakakou P, et al. Taxane resistance in prostate cancer is mediated by decreased drug-target engagement. The Journal of Clinical Investigation. 130: 3287-3298. PMID 32478682 DOI: 10.1172/Jci132184 |
0.445 |
|
| 2020 |
Galletti G, Zhang C, Gjyrezi A, Cleveland K, Zhang J, Powell S, Thakkar PV, Betel D, Shah MA, Giannakakou P. Microtubule engagement with taxane is altered in taxane-resistant gastric cancer. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 32321717 DOI: 10.1158/1078-0432.Ccr-19-3018 |
0.35 |
|
| 2020 |
Brown LC, Halabi S, Schonhoft J, Luo J, Nanus DM, Giannakakou P, Szmulewitz RZ, Danila DC, Healy P, Anand M, Somarelli J, Scher HI, Wenstrup R, Berry WR, Tagawa ST, et al. Association of circulating tumor cell chromosomal instability with worse outcomes in men with mCRPC treated with abiraterone or enzalutamide. Journal of Clinical Oncology. 38: 183-183. DOI: 10.1200/Jco.2020.38.6_Suppl.183 |
0.326 |
|
| 2020 |
Gupta S, Halabi S, Kemeny G, Anand M, Nanus DM, Giannakakou P, George DJ, Gregory S, Armstrong AJ. Circulating tumor cell (CTC) genomic signatures of hormone therapy resistance in men with metastatic castration-resistant prostate cancer (mCRPC). Journal of Clinical Oncology. 38: 147-147. DOI: 10.1200/Jco.2020.38.6_Suppl.147 |
0.377 |
|
| 2020 |
Mukhtar E, Worroll D, Galletti G, Schuster S, Piha-Paul SA, Giannakakou P. Abstract 3196: Analysis of taxane drug target engagement of microtubules in circulating tumor cells from metastatic castration resistant prostate cancer patients treated with CRLX301, a nanoparticle of docetaxel Clinical Trials. DOI: 10.1158/1538-7445.Am2020-3196 |
0.429 |
|
| 2020 |
Sarkar S, Thakkar PK, Lenz H, Enzinger P, Ko AH, Ocean AJ, Lu Y, Zhang C, Bhinder B, Plotnikova O, Kotlov N, Frenkel F, Bagaev A, Elemento O, Betel D, ... Giannakakou P, et al. Abstract 2011: HER2 expression and M2-like tumor infiltrating macrophages associated with Cabazitaxel activity in gastric cancer Clinical Trials. DOI: 10.1158/1538-7445.Am2020-2011 |
0.309 |
|
| 2019 |
Madhukar NS, Khade PK, Huang L, Gayvert K, Galletti G, Stogniew M, Allen JE, Giannakakou P, Elemento O. A Bayesian machine learning approach for drug target identification using diverse data types. Nature Communications. 10: 5221. PMID 31745082 DOI: 10.1038/S41467-019-12928-6 |
0.36 |
|
| 2019 |
Tagawa ST, Antonarakis ES, Gjyrezi A, Galletti G, Giannakakou P. Clinical Significance of AR-V567es in Prostate Cancer-Response. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 25: 6010-6011. PMID 31575715 DOI: 10.1158/1078-0432.Ccr-19-1820 |
0.339 |
|
| 2019 |
Armstrong AJ, Gupta S, Healy P, Kemeny G, Leith B, Zalutsky MR, Spritzer C, Davies C, Rothwell C, Ware K, Somarelli JA, Wood K, Ribar T, Giannakakou P, Zhang J, et al. Pharmacodynamic study of radium-223 in men with bone metastatic castration resistant prostate cancer. Plos One. 14: e0216934. PMID 31136607 DOI: 10.1371/Journal.Pone.0216934 |
0.357 |
|
| 2019 |
Armstrong AJ, Halabi S, Luo J, Nanus DM, Giannakakou P, Szmulewitz RZ, Danila DC, Healy P, Anand M, Rothwell CJ, Rasmussen J, Thornburg B, Berry WR, Wilder RS, Lu C, et al. Prospective Multicenter Validation of Androgen Receptor Splice Variant 7 and Hormone Therapy Resistance in High-Risk Castration-Resistant Prostate Cancer: The PROPHECY Study. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. JCO1801731. PMID 30865549 DOI: 10.1200/Jco.18.01731 |
0.373 |
|
| 2019 |
Worroll D, Galletti G, Gjyrezi A, Nanus D, Tagawa ST, Giannakakou P. Androgen receptor nuclear localization correlates with AR-V7 mRNA expression in circulating tumor cells (CTCs) from metastatic castration resistance prostate cancer patients. Physical Biology. PMID 30763921 DOI: 10.1088/1478-3975/Ab073A |
0.407 |
|
| 2019 |
Molina A, Christos P, Hackett A, Nordquist L, Gelmann E, Stein M, Sternberg C, Beltran H, Gracey L, Galletti G, Giannakakou P, Nanus DM, Tagawa ST. Abstract CT097: Phase I trial of apalutamide plus abiraterone acetate, docetaxel, and prednisone in patients with metastatic castration-resistant prostate cancer (mCRPC) Cancer Research. 79. DOI: 10.1158/1538-7445.Sabcs18-Ct097 |
0.338 |
|
| 2019 |
Halima A, Zhang J, Galletti G, Ocean AJ, Giannakakou P. Abstract 454: Transferrin receptor identifies a novel circulating tumor cell population in patients with pancreatic cancer with a unique metastasis-associated molecular signature Cancer Research. DOI: 10.1158/1538-7445.Sabcs18-454 |
0.362 |
|
| 2019 |
Thakkar PV, Kita K, Galletti G, Madhukar NS, Cleveland K, Barasoain I, Diaz JF, Elemento O, Shah MA, Giannakakou P. Abstract 3817: Systems biology identifies that Gleevec reverses taxane resistance in solid tumors by selective inhibition of a novel +Tip microtubule-binding variant Cancer Research. 79: 3817-3817. DOI: 10.1158/1538-7445.Sabcs18-3817 |
0.439 |
|
| 2019 |
Gjyrezi A, Galletti G, Zhang J, Bareja R, Halima A, Worroll D, Nanus D, Tagawa S, Beltran H, Giannakakou P. Abstract 451: Transferrin Receptor identifies a distinct pool of circulating tumor cells from metastatic prostate cancer patients with unique molecular profiles enriched in AR variants Cancer Research. 79: 451-451. DOI: 10.1158/1538-7445.Am2019-451 |
0.437 |
|
| 2019 |
Kim S, Jamalruddin MA, Mukhtar E, Miller M, Baxt L, Kargman S, Stamford A, Meinke P, Giannakakou P. Abstract 1017: Novel inhibitors of AR-v7 nuclear import: new therapeutic opportunities for CRPC Cancer Research. 79: 1017-1017. DOI: 10.1158/1538-7445.Am2019-1017 |
0.411 |
|
| 2018 |
Tagawa ST, Antonarakis ES, Gjyrezi A, Galletti G, Kim S, Worroll D, Stewart J, Zaher A, Szatrowski TP, Ballman KV, Kita K, Tasaki S, Bai Y, Portella L, Kirby BJ, ... ... Giannakakou P, et al. Expression of AR-V7 and ARv567es in circulating tumor cells correlates with outcomes to taxane therapy in men with metastatic prostate cancer treated in TAXYNERGY. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 30301829 DOI: 10.1158/1078-0432.Ccr-18-0320 |
0.406 |
|
| 2018 |
Gupta S, Hovelson DH, Tomlins SA, Kemeny G, Liu C, George DJ, Rothwell C, Anand M, Nanus DM, Giannakakou P, Gregory S, Armstrong AJ. Analysis of genomic alterations in matched circulating tumor cell DNA (CTC DNA) and plasma tumor DNA (ctDNA) in men with metastatic castration resistant prostate cancer (mCRPC). Journal of Clinical Oncology. 36: 5065-5065. DOI: 10.1200/Jco.2018.36.15_Suppl.5065 |
0.303 |
|
| 2018 |
Armstrong AJ, Halabi S, Luo J, Nanus DM, Giannakakou P, Szmulewitz RZ, Danila DC, Healy P, Anand M, Rothwell C, Silberstein J, Galletti G, Somarelli J, Gupta S, Gregory S, et al. The PROPHECY trial: Multicenter prospective trial of circulating tumor cell (CTC) AR-V7 detection in men with mCRPC receiving abiraterone (A) or enzalutamide (E). Journal of Clinical Oncology. 36: 5004-5004. DOI: 10.1200/Jco.2018.36.15_Suppl.5004 |
0.305 |
|
| 2017 |
Galletti G, Worroll D, Nanus DM, Giannakakou P. Using circulating tumor cells to advance precision medicine in prostate cancer. Journal of Cancer Metastasis and Treatment. 3: 190-205. PMID 29707651 DOI: 10.20517/2394-4722.2017.45 |
0.39 |
|
| 2017 |
Antonarakis ES, Tagawa ST, Galletti G, Worroll D, Ballman K, Vanhuyse M, Sonpavde G, North S, Albany C, Tsao CK, Stewart J, Zaher A, Szatrowski T, Zhou W, Gjyrezi A, ... ... Giannakakou P, et al. Randomized, Noncomparative, Phase II Trial of Early Switch From Docetaxel to Cabazitaxel or Vice Versa, With Integrated Biomarker Analysis, in Men With Chemotherapy-Naïve, Metastatic, Castration-Resistant Prostate Cancer. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. JCO2017724138. PMID 28632486 DOI: 10.1200/Jco.2017.72.4138 |
0.384 |
|
| 2017 |
Giannakakou P, Antonarakis ES, Galletti G, Worroll D, Stewart J, Zaher A, Szatrowski TP, Zhou W, Ballman KV, Vanhuyse M, Gjyrezi A, Tasaki S, Bai Y, Portella L, Kirby BJ, et al. AR nuclear localization and microtubule bundling as markers of docetaxel and cabazitaxel sensitivity in metastatic castration-resistant prostate cancer (mCRPC): Prospective biomarker analysis from TAXYNERGY. Journal of Clinical Oncology. 35: 134-134. DOI: 10.1200/Jco.2017.35.6_Suppl.134 |
0.343 |
|
| 2017 |
Thakkar PV, Kita K, Galletti G, Cleveland K, Barasoain I, Diaz JF, Shah MA, Giannakakou P. Abstract 4169: A novel, short isoform of the +Tip microtubule binding protein CLIP170 confers taxane resistance in gastric cancer Cancer Research. 77: 4169-4169. DOI: 10.1158/1538-7445.Am2017-4169 |
0.434 |
|
| 2017 |
Gjyrezi A, Galletti G, Strati A, Kim S, Lianidou E, Nanus DM, Luo J, Antonarakis E, Tagawa ST, Armstrong A, Giannakakou P. Abstract 2736: A digital droplet PCR assay for the quantitation of androgen receptor and splice variant expression in CTCs from metastatic castration resistant prostate cancer patients Cancer Research. 77: 2736-2736. DOI: 10.1158/1538-7445.Am2017-2736 |
0.403 |
|
| 2017 |
Galletti G, Kallergi G, Saxena A, Aggouraki D, Stournaras C, Georgoulias V, McGraw TE, Altorki N, Giannakakou P. Abstract 1713: Transferrin receptor 1 (TfR) as marker for circulating tumor cells (CTCs) identification in NSCLC Cancer Research. 77: 1713-1713. DOI: 10.1158/1538-7445.Am2017-1713 |
0.371 |
|
| 2017 |
Kim S, Jamalruddin MA, Giannakakou P. Abstract 1590: High intranuclear mobility of AR-v7 reveals distinct mode of transcriptional activity in prostate cancer with important therapeutic implications Endocrinology. 77: 1590-1590. DOI: 10.1158/1538-7445.Am2017-1590 |
0.352 |
|
| 2016 |
Jing H, Hu J, He B, Negrón Abril YL, Stupinski J, Weiser K, Carbonaro M, Chiang YL, Southard T, Giannakakou P, Weiss RS, Lin H. A SIRT2-Selective Inhibitor Promotes c-Myc Oncoprotein Degradation and Exhibits Broad Anticancer Activity. Cancer Cell. 29: 767-768. PMID 27165747 DOI: 10.1016/J.Ccell.2016.04.005 |
0.715 |
|
| 2016 |
Jing H, Hu J, He B, Negrón Abril YL, Stupinski J, Weiser K, Carbonaro M, Chiang YL, Southard T, Giannakakou P, Weiss RS, Lin H. A SIRT2-Selective Inhibitor Promotes c-Myc Oncoprotein Degradation and Exhibits Broad Anticancer Activity. Cancer Cell. 29: 607. PMID 27070708 DOI: 10.1016/j.ccell.2016.03.011 |
0.637 |
|
| 2016 |
Jing H, Hu J, He B, Negrón Abril YL, Stupinski J, Weiser K, Carbonaro M, Chiang YL, Southard T, Giannakakou P, Weiss RS, Lin H. A SIRT2-Selective Inhibitor Promotes c-Myc Oncoprotein Degradation and Exhibits Broad Anticancer Activity. Cancer Cell. 29: 297-310. PMID 26977881 DOI: 10.1016/j.ccell.2016.02.007 |
0.699 |
|
| 2016 |
Tagawa ST, Antonarakis ES, Saad F, Vanhuyse M, Sonpavde G, North SA, Albany C, Tsao C, Stewart J, Zaher A, Szatrowski TP, Zhou W, Galletti G, Worroll D, Eisenberger MA, ... ... Giannakakou P, et al. TAXYNERGY: Randomized trial of early switch from first-line docetaxel (D) to cabazitaxel (C) or vice versa with circulating tumor cell (CTC) biomarkers in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC). Journal of Clinical Oncology. 34: 5007-5007. DOI: 10.1200/Jco.2016.34.15_Suppl.5007 |
0.372 |
|
| 2016 |
Madhukar NS, Khade P, Huang L, Gayvert K, Galletti G, Giannakakou P, Elemento O. Abstract LB-106: Using a data-driven Bayesian approach to predict the targets of orphan small molecules and ways to overcome drug resistance Cancer Research. 76. DOI: 10.1158/1538-7445.Am2016-Lb-106 |
0.377 |
|
| 2016 |
Worroll D, Galletti G, Nanus DM, Tagawa ST, Giannakakou P. Abstract 4971: Quantitative image analysis of androgen receptor (AR) and tubulin biomarker profiles in circulating tumor cells (CTCs) from metastatic castration resistant prostate cancer (mCRPC) patients Cancer Research. 76: 4971-4971. DOI: 10.1158/1538-7445.Am2016-4971 |
0.401 |
|
| 2016 |
Galletti G, Zhang C, Cleveland K, Betel D, Shah M, Giannakakou P. Abstract 4938: Molecular mechanisms of intrinsic resistance to taxanes in gastric cancer Cancer Research. 76: 4938-4938. DOI: 10.1158/1538-7445.Am2016-4938 |
0.442 |
|
| 2016 |
Zhang J, Gjyrezi A, Thakkar P, Galletti G, Verma A, Elemento O, Giannakakou P. Abstract 3489: Elucidation of taxane resistance in prostate cancer through RNA-Seq analysis of circulating tumor cells Cancer Research. 76: 3489-3489. DOI: 10.1158/1538-7445.Am2016-3489 |
0.415 |
|
| 2016 |
Kim S, Jamalruddin MA, Portella L, Giannakakou P. Abstract 3486: Dissecting the mechanism of AR-v7 nuclear translocation in prostate cancer Cancer Research. 76: 3486-3486. DOI: 10.1158/1538-7445.Am2016-3486 |
0.42 |
|
| 2016 |
Kita K, Galletti G, Cleveland K, Zhang C, Barasoain I, Díaz JF, Betel D, Shah MA, Giannakakou P. Abstract 2932: Impaired taxane binding to MT pore sites mediates intrinsic drug resistance in diffuse gastric cancer Cancer Research. 76: 2932-2932. DOI: 10.1158/1538-7445.Am2016-2932 |
0.409 |
|
| 2016 |
Khade P, Giannakakou P. Abstract 2896: 4E-BP1 hyper-phosphorylation senses microtubule damage and plays a critical role in taxane antitumor activity Cancer Research. 76: 2896-2896. DOI: 10.1158/1538-7445.Am2016-2896 |
0.396 |
|
| 2016 |
Berger A, Kim S, Gjyrezi A, Galletti G, Sboner A, Rubin MA, Tagawa S, Giannakakou P, rickman DS. Abstract 2125: ERG and AR-v7 involvement in taxane resistance of metastatic castration-resistant prostate cancers Cancer Research. 76: 2125-2125. DOI: 10.1158/1538-7445.Am2016-2125 |
0.37 |
|
| 2015 |
Nanus DM, Giannakakou P. CANCER. Cancer therapies that are gone with the Wnt. Science (New York, N.Y.). 349: 1283-4. PMID 26383936 DOI: 10.1126/Science.Aad2448 |
0.405 |
|
| 2015 |
Diamond E, Molina AM, Carbonaro M, Akhtar NH, Giannakakou P, Tagawa ST, Nanus DM. Cytotoxic chemotherapy in the treatment of advanced renal cell carcinoma in the era of targeted therapy. Critical Reviews in Oncology/Hematology. PMID 26321263 DOI: 10.1016/J.Critrevonc.2015.08.007 |
0.677 |
|
| 2015 |
Tagawa ST, Galletti G, Antonarakis ES, Tasaki S, Gjyrezi A, Worroll D, Portella L, Kirby BJ, Stewart J, Zaher A, Saad F, Vanhuyse M, Suri S, Lannin TB, Gruber C, ... ... Giannakakou P, et al. Baseline analysis of circulating tumor cell (CTC) enumeration and androgen receptor (AR) localization in men with metastatic castration-resistant prostate cancer (mCRPC) in TAXYNERGY. Journal of Clinical Oncology. 33: 5031-5031. DOI: 10.1200/Jco.2015.33.15_Suppl.5031 |
0.411 |
|
| 2015 |
Basciano P, Li X, Matakas J, Liu S, Giandomenico SD, Sen S, Evans T, Scandura J, Guzman M, Giannakakou P. Abstract 5096: ALIBI: a novel, truncated tubulin isotype in AML and stem cells Cancer Research. 75: 5096-5096. DOI: 10.1158/1538-7445.Am2015-5096 |
0.355 |
|
| 2015 |
Galletti G, Cheung C, Rickman DS, Giannakakou P. Abstract 4311: Molecular basis of interaction between ERG and microtubule inhibitors in CRPC patients Cancer Research. 75: 4311-4311. DOI: 10.1158/1538-7445.Am2015-4311 |
0.474 |
|
| 2015 |
Kita K, Galletti G, Cleveland K, Thakkar PV, Gjyrezi A, Zhang C, Barasoain I, Díaz JF, Betel D, Shah MA, Giannakakou P. Abstract 3600: Impaired taxane binding to MTs in intrinsically taxane resistant gastric cancer cells without β-tubulin mutation Cancer Research. 75: 3600-3600. DOI: 10.1158/1538-7445.Am2015-3600 |
0.425 |
|
| 2015 |
Kim S, Portella L, Giannakakou P. Abstract 3451: Distinct nuclear translocation mechanism of androgen receptor variant ARv7 Cancer Research. 75: 3451-3451. DOI: 10.1158/1538-7445.Am2015-3451 |
0.454 |
|
| 2015 |
Khade P, Giannakakou P. Abstract 2121: Microtubule-regulated mRNA translation signaling and therapeutic implications in cancer Cancer Research. 75: 2121-2121. DOI: 10.1158/1538-7445.Am2015-2121 |
0.36 |
|
| 2015 |
Zong H, Penthala NR, Sonar VN, Giannakakou P, Roboz GJ, Crooks PA, Guzman ML. Abstract 1667: Targeting acute myelogenous leukemia with novel combrestatin analogs and development of predictors of response Cancer Research. 75: 1667-1667. DOI: 10.1158/1538-7445.Am2015-1667 |
0.412 |
|
| 2015 |
Madhukar NS, Huang L, Khade P, Gayvert K, Giannakakou P, Elemento O. Abstract B162: Small molecule target prediction and identification of novel anti-cancer compounds using a data-driven bayesian approach Molecular Cancer Therapeutics. 14. DOI: 10.1158/1535-7163.Targ-15-B162 |
0.351 |
|
| 2015 |
Tagawa S, Galletti G, Antonarakis E, Tasaki S, Gjyrezi A, Worroll D, Portella L, Kirby B, Stewart J, Zaher A, Saad F, Vanhuyse M, Suri S, Lannin T, Gruber C, ... ... Giannakakou P, et al. 2563 Screening and baseline analysis of circulating tumor cell (CTC) counts and androgen receptor (AR) localization with clinical characteristics of men with metastatic castration-resistant prostate cancer (mCRPC) in TAXYNERGY European Journal of Cancer. 51: S498-S499. DOI: 10.1016/S0959-8049(16)31382-X |
0.388 |
|
| 2014 |
Galletti G, Matov A, Beltran H, Fontugne J, Miguel Mosquera J, Cheung C, MacDonald TY, Sung M, O'Toole S, Kench JG, Suk Chae S, Kimovski D, Tagawa ST, Nanus DM, Rubin MA, ... ... Giannakakou P, et al. ERG induces taxane resistance in castration-resistant prostate cancer. Nature Communications. 5: 5548. PMID 25420520 DOI: 10.1038/Ncomms6548 |
0.389 |
|
| 2014 |
Fojo T, Giannakakou P. Decade in review-funding in cancer research: National Cancer Institute awards-a work in progress. Nature Reviews. Clinical Oncology. 11: 634-6. PMID 25311348 DOI: 10.1038/Nrclinonc.2014.173 |
0.319 |
|
| 2014 |
Khade PK, Giannakakou P. RABbing cancer the wrong way. Proceedings of the National Academy of Sciences of the United States of America. 111: 11230-1. PMID 25053807 DOI: 10.1073/Pnas.1410788111 |
0.39 |
|
| 2014 |
Harkcom WT, Ghosh AK, Sung MS, Matov A, Brown KD, Giannakakou P, Jaffrey SR. NAD+ and SIRT3 control microtubule dynamics and reduce susceptibility to antimicrotubule agents. Proceedings of the National Academy of Sciences of the United States of America. 111: E2443-52. PMID 24889606 DOI: 10.1073/Pnas.1404269111 |
0.31 |
|
| 2014 |
Galletti G, Portella L, Tagawa ST, Kirby BJ, Giannakakou P, Nanus DM. Circulating tumor cells in prostate cancer diagnosis and monitoring: an appraisal of clinical potential. Molecular Diagnosis & Therapy. 18: 389-402. PMID 24809501 DOI: 10.1007/S40291-014-0101-8 |
0.382 |
|
| 2014 |
Thadani-Mulero M, Portella L, Sun S, Sung M, Matov A, Vessella RL, Corey E, Nanus DM, Plymate SR, Giannakakou P. Androgen receptor splice variants determine taxane sensitivity in prostate cancer. Cancer Research. 74: 2270-82. PMID 24556717 DOI: 10.1158/0008-5472.Can-13-2876 |
0.419 |
|
| 2014 |
Galletti G, Sung MS, Vahdat LT, Shah MA, Santana SM, Altavilla G, Kirby BJ, Giannakakou P. Isolation of breast cancer and gastric cancer circulating tumor cells by use of an anti HER2-based microfluidic device. Lab On a Chip. 14: 147-56. PMID 24202699 DOI: 10.1039/C3Lc51039E |
0.383 |
|
| 2014 |
Sung M, Giannakakou P. BRCA1 regulates microtubule dynamics and taxane-induced apoptotic cell signaling Oncogene. 33: 1418-1428. PMID 23524581 DOI: 10.1038/Onc.2013.85 |
0.416 |
|
| 2014 |
Tasaki S, Sung M, Matov A, Galletti G, Diamond E, Bander N, Zhou K, Tagawa S, Nanus D, Giannakakou P. Abstract 923: Analysis of microtubule perturbations and androgen receptor localization in circulating tumor cells from castration resistant prostate cancer patients as predictive biomarkers of clinical response to docetaxel chemotherapy Cancer Research. 74: 923-923. DOI: 10.1158/1538-7445.Am2014-923 |
0.475 |
|
| 2014 |
Galletti G, Cleveland K, Zhang C, Gjyrezi A, Matov A, Betel D, Shah MA, Giannakakou P. Abstract 897: Elucidating the molecular basis of intrinsic taxane resistance in gastric cancer Cancer Research. 74: 897-897. DOI: 10.1158/1538-7445.Am2014-897 |
0.43 |
|
| 2014 |
Portella L, Giannakakou P. Abstract 2112: AR splice variants ARv7 and ARv567 utilize different mechanisms of cytoplasmic trafficking and nuclear translocation: Therapeutic implications for PC Cancer Research. 74: 2112-2112. DOI: 10.1158/1538-7445.Am2014-2112 |
0.452 |
|
| 2014 |
Kita K, Tran A, Brown LM, Hassane DC, Carey S, Matov A, Reinhart-King CA, Giannakakou P. Abstract 1158: Microtubule perturbation regulates remodeling of tumor microenvironment by modulating the composition of tumor cell secretome Cancer Research. 74: 1158-1158. DOI: 10.1158/1538-7445.Am2014-1158 |
0.429 |
|
| 2013 |
Gakhar G, Navarro VN, Jurish M, Lee GY, Tagawa ST, Akhtar NH, Seandel M, Geng Y, Liu H, Bander NH, Giannakakou P, Christos PJ, King MR, Nanus DM. Circulating tumor cells from prostate cancer patients interact with E-selectin under physiologic blood flow. Plos One. 8: e85143. PMID 24386459 DOI: 10.1371/Journal.Pone.0085143 |
0.337 |
|
| 2013 |
Galletti G, Cleveland K, Matov A, Hayes JE, Klein RJ, Hassane DC, Nicacio LV, Giannakakou P, Shah MA. Clinical and preclinical evaluation of taxane sensitivity in gastric cancer (GC): Relevance of GC histology. Journal of Clinical Oncology. 31: 37-37. DOI: 10.1200/Jco.2013.31.4_Suppl.37 |
0.337 |
|
| 2013 |
Antonarakis ES, Giannakakou P, Kirby BJ, Nicacio LV, Eisenberger MA, Nanus DM, Tagawa ST. TAXYNERGY (NCT01718353): A randomized phase II trial examining an early switch from first-line docetaxel to cabazitaxel, or cabazitaxel to docetaxel, in men with metastatic castration-resistant prostate cancer (mCRPC). Journal of Clinical Oncology. 31: TPS5100-TPS5100. DOI: 10.1200/Jco.2013.31.15_Suppl.Tps5100 |
0.387 |
|
| 2013 |
Galletti G, Beltran H, Matov A, Fontugne J, Mosquera JM, Fazli L, Tagawa S, Nanus D, Gleave M, Rubin M, Giannakakou P, Rickman DS. Abstract LB-59: ERG induces taxane resistance in castration-resistant prostate cancer. Cancer Research. 73. DOI: 10.1158/1538-7445.Am2013-Lb-59 |
0.469 |
|
| 2013 |
Tran A, Kita K, Matov A, Hassane DC, Brown LM, Giannakakou P. Abstract 5162: Microtubule stabilization alters tumor secretome and fibroblast activation. Cancer Research. 73: 5162-5162. DOI: 10.1158/1538-7445.Am2013-5162 |
0.425 |
|
| 2013 |
Portella L, Thadani-Mulero M, Matov A, Nanus DM, Plymate SR, Giannakakou P. Abstract 4081: Taxane sensitivity in prostate cancer is determined by androgen receptor splice variants. Cancer Research. 73: 4081-4081. DOI: 10.1158/1538-7445.Am2013-4081 |
0.416 |
|
| 2013 |
Sung MS, Gjyrezi A, Lee GY, Matov A, Galletti G, Loftus M, Syed Y, Lannin T, Hristov A, Mason C, Tagawa S, Kirby B, Nanus D, Giannakakou P. Abstract 3492: Using CTCs to interrogate mechanisms of taxane resistance in the prospective TAXYNERGY clinical trial in prostate cancer. Cancer Research. 73: 3492-3492. DOI: 10.1158/1538-7445.Am2013-3492 |
0.433 |
|
| 2013 |
Matov A, Kimovski D, Galletti G, Chan N, Pera B, Harkcom WT, Rickman DS, Giannakakou P. Abstract 2888: Computational analysis of microtubule dynamics for personalized cancer therapy. Cancer Research. 73: 2888-2888. DOI: 10.1158/1538-7445.Am2013-2888 |
0.455 |
|
| 2013 |
Carbonaro M, Hassane D, Giannakakou P. Abstract 2318: The microtubule cytoskeleton in the dynamic regulation of translation: implications for taxane therapy. Cancer Research. 73: 2318-2318. DOI: 10.1158/1538-7445.Am2013-2318 |
0.728 |
|
| 2013 |
Galletti G, Kirby B, Vahdat LT, Giannakakou P. Abstract 1467: Development of a HER2-based GEDI microfluidic device for the molecular characterization of CTCs from metastatic breast cancer patients. Cancer Research. 73: 1467-1467. DOI: 10.1158/1538-7445.Am2013-1467 |
0.414 |
|
| 2012 |
Nanus DM, Loftus M, Akhtar NH, Tagawa ST, Beltran H, Goodman OB, Zhou XK, Bander NH, Giannakakou P. Prospective analysis of prostate cancer (PC) circulating tumor cells (CTCs) to predict response to docetaxel (DOC) chemotherapy. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 30: 100. PMID 28143088 DOI: 10.1200/jco.2012.30.5_suppl.100 |
0.337 |
|
| 2012 |
Nanus DM, Loftus M, Akhtar NH, Tagawa ST, Beltran H, Goodman OB, Zhou XK, Bander NH, Giannakakou P. Prospective analysis of prostate cancer (PC) circulating tumor cells (CTCs) to predict response to docetaxel (DOC) chemotherapy. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 30: 100. PMID 27968032 DOI: 10.1200/Jco.2012.30.5_Suppl.100 |
0.443 |
|
| 2012 |
Diamond E, Lee GY, Akhtar NH, Kirby BJ, Giannakakou P, Tagawa ST, Nanus DM. Isolation and characterization of circulating tumor cells in prostate cancer. Frontiers in Oncology. 2: 131. PMID 23087897 DOI: 10.3389/Fonc.2012.00131 |
0.374 |
|
| 2012 |
Thadani-Mulero M, Nanus DM, Giannakakou P. Androgen receptor on the move: boarding the microtubule expressway to the nucleus. Cancer Research. 72: 4611-5. PMID 22987486 DOI: 10.1158/0008-5472.Can-12-0783 |
0.44 |
|
| 2012 |
Kirby BJ, Jodari M, Loftus MS, Gakhar G, Pratt ED, Chanel-Vos C, Gleghorn JP, Santana SM, Liu H, Smith JP, Navarro VN, Tagawa ST, Bander NH, Nanus DM, Giannakakou P. Functional characterization of circulating tumor cells with a prostate-cancer-specific microfluidic device. Plos One. 7: e35976. PMID 22558290 DOI: 10.1371/Journal.Pone.0035976 |
0.451 |
|
| 2012 |
Carbonaro M, Escuin D, O'Brate A, Thadani-Mulero M, Giannakakou P. Microtubules regulate hypoxia-inducible factor-1α protein trafficking and activity: implications for taxane therapy. The Journal of Biological Chemistry. 287: 11859-69. PMID 22367210 DOI: 10.1074/Jbc.M112.345587 |
0.691 |
|
| 2012 |
Thadani-Mulero M, Plymate SR, Giannakakou P. Abstract 285: Androgen receptor splice variants determine taxane sensitivity in prostate cancer Cancer Research. 72: 285-285. DOI: 10.1158/1538-7445.Am2012-285 |
0.422 |
|
| 2012 |
Galletti G, Kirby B, Vahdat L, Giannakakou P. Abstract 2376: Development of a novel microfluidic device for the capture and molecular characterization of circulating tumor cells from metastatic breast cancer patients Cancer Research. 72: 2376-2376. DOI: 10.1158/1538-7445.Am2012-2376 |
0.413 |
|
| 2012 |
Tran AD, Brown LM, Hassane DC, Giannakakou P. Abstract 1502: Microtubule stabilization alters tumor secretome and fibroblast activation Cancer Research. 72: 1502-1502. DOI: 10.1158/1538-7445.Am2012-1502 |
0.424 |
|
| 2011 |
Jodari M, Loftus M, Gleghorn J, Gakhar G, Pratt E, Tagawa ST, Bander NH, Giannakakou P, Kirby B, Nanus DM. Capture and analysis of prostate cancer circulating tumor cells (CTCS) using geometrically enhanced differential immunocapture (GEDI). Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 29: 53. PMID 27968401 DOI: 10.1200/Jco.2011.29.7_Suppl.53 |
0.338 |
|
| 2011 |
Darshan MS, Loftus MS, Thadani-Mulero M, Levy BP, Escuin D, Zhou XK, Gjyrezi A, Chanel-Vos C, Shen R, Tagawa ST, Bander NH, Nanus DM, Giannakakou P. Taxane-induced blockade to nuclear accumulation of the androgen receptor predicts clinical responses in metastatic prostate cancer. Cancer Research. 71: 6019-29. PMID 21799031 DOI: 10.1158/0008-5472.Can-11-1417 |
0.441 |
|
| 2011 |
Wang X, Li J, Wang Y, Koenig L, Gjyrezi A, Giannakakou P, Shin EH, Tighiouart M, Chen ZG, Nie S, Shin DM. A folate receptor-targeting nanoparticle minimizes drug resistance in a human cancer model. Acs Nano. 5: 6184-94. PMID 21728341 DOI: 10.1021/Nn200739Q |
0.37 |
|
| 2011 |
Kanakkanthara A, Wilmes A, O'Brate A, Escuin D, Chan A, Gjyrezi A, Crawford J, Rawson P, Kivell B, Northcote PT, Hamel E, Giannakakou P, Miller JH. Peloruside- and laulimalide-resistant human ovarian carcinoma cells have βI-tubulin mutations and altered expression of βII- and βIII-tubulin isotypes. Molecular Cancer Therapeutics. 10: 1419-29. PMID 21653684 DOI: 10.1158/1535-7163.Mct-10-1057 |
0.388 |
|
| 2011 |
Kauh J, Chanel-Vos C, Escuin D, Fanucchi MP, Harvey RD, Saba N, Shin DM, Gal A, Pan L, Kutner M, Ramalingam SS, Bender L, Marcus A, Giannakakou P, Khuri FR. Farnesyl transferase expression determines clinical response to the docetaxel-lonafarnib combination in patients with advanced malignancies. Cancer. 117: 4049-59. PMID 21365629 DOI: 10.1002/Cncr.26004 |
0.369 |
|
| 2011 |
Carbonaro M, O'Brate A, Giannakakou P. Microtubule disruption targets HIF-1alpha mRNA to cytoplasmic P-bodies for translational repression. The Journal of Cell Biology. 192: 83-99. PMID 21220510 DOI: 10.1083/Jcb.201004145 |
0.689 |
|
| 2011 |
Jeske S, Tagawa ST, Olowokure O, Selzer J, Giannakakou P, Nanus DM. Carboplatin plus paclitaxel therapy after docetaxel in men with metastatic castrate resistant prostate cancer. Urologic Oncology. 29: 676-81. PMID 20451413 DOI: 10.1016/J.Urolonc.2009.12.023 |
0.384 |
|
| 2011 |
Wang X, Li J, Wang Y, Koenig L, Gjyrezi A, Giannakakou P, Shin EH, Tighiouart M, Chen Z, Nie S, Shin DM. Abstract LB-196: A folate receptor-targeted nanoparticle minimizes multidrug resistance in human cancer xenograft model Cancer Research. 71. DOI: 10.1158/1538-7445.Am2011-Lb-196 |
0.369 |
|
| 2011 |
Sung M, Giannakakou P. Abstract 696: BRCA1-mediated ubiquitination of tubulin may serve as a signal for taxol-induced apoptosis Cancer Research. 71: 696-696. DOI: 10.1158/1538-7445.Am2011-696 |
0.462 |
|
| 2011 |
Gjyrezi A, Gumus ZH, Siso-Nadal F, McDonagh P, Khalil I, Weinstein H, Giannakakou P. Abstract 4911: Molecular investigation of the FTI/Taxol synergy using an integrated framework of transcriptome analysis Cancer Research. 71: 4911-4911. DOI: 10.1158/1538-7445.Am2011-4911 |
0.389 |
|
| 2011 |
Loftus M, Jodari-Karimi M, Gakhar G, Pratt E, Santana S, Rubin M, Bander N, Navarro V, Tagawa S, Kirby B, Nanus D, Giannakakou P. Abstract 4891: Molecular and functional analysis of circulating tumor cells in castrate resistant prostate cancer using a geometrically enhanced microfluidic device based on PSMA immunocapture Cancer Research. 71: 4891-4891. DOI: 10.1158/1538-7445.Am2011-4891 |
0.4 |
|
| 2011 |
Tran AD, Giannakakou P. Abstract 435: MT regulation of tumor-dependent microenvironment remodeling Cancer Research. 71: 435-435. DOI: 10.1158/1538-7445.Am2011-435 |
0.417 |
|
| 2011 |
Thadani-Mulero M, Plymate SR, Giannakakou P. Abstract 2163: Microtubule-dependent regulation of a constitutively active androgen receptor splice variant Cancer Research. 71: 2163-2163. DOI: 10.1158/1538-7445.Am2011-2163 |
0.433 |
|
| 2010 |
Chanel-Vos C, Giannakakou P. CENP-E checks in microtubule-drug resistance. Cell Cycle (Georgetown, Tex.). 9: 1456. PMID 20421712 DOI: 10.4161/Cc.9.8.11382 |
0.303 |
|
| 2010 |
Basciano PA, Borras DE, Rodriguez C, Giannakakou P. Abstract 835: Functional studies of the hematopoietic-specific tubulin isotype Hβ-1 Cancer Research. 70: 835-835. DOI: 10.1158/1538-7445.Am10-835 |
0.384 |
|
| 2010 |
Chanel-Vos C, Gjyrezi A, Giannakakou P. Abstract 4415: Role for the protein farnesyltransferase in the regulation of microtubule dynamics Cancer Research. 70: 4415-4415. DOI: 10.1158/1538-7445.Am10-4415 |
0.393 |
|
| 2010 |
Carson B, Carbonaro M, O'Brate A, Giannakakou P. Abstract 4079: Loss of microtubule-dependent HIF regulation in renal cell carcinoma Cancer Research. 70: 4079-4079. DOI: 10.1158/1538-7445.Am10-4079 |
0.719 |
|
| 2010 |
Thadani-Mulero M, Darshan M, Giannakakou P. Abstract 4076: Taxanes inhibit the microtubule-dependent androgen receptor trafficking and signaling in prostate cancer Cancer Research. 70: 4076-4076. DOI: 10.1158/1538-7445.Am10-4076 |
0.445 |
|
| 2010 |
Carbonaro M, O'Brate A, Giannakakou P. Abstract 4059: Taxol inhibits HIF-1α translation by targeting HIF-1α mRNA to P-bodies following microtubule disruption Cancer Research. 70: 4059-4059. DOI: 10.1158/1538-7445.Am10-4059 |
0.706 |
|
| 2010 |
Gjyrezi A, Gümüş ZH, Wyngaert IVd, Talloen W, Göhlmann HWH, Weinstein H, Giannakakou P. Abstract 115: An integrated framework of transcriptome analysis leads to mechanistic insights into the FTI/Taxol synergy Cancer Research. 70: 115-115. DOI: 10.1158/1538-7445.Am10-115 |
0.388 |
|
| 2010 |
Loftus M, Gleghorn J, Pratt E, Bander N, Nanus D, Kirby B, Giannakakou P. Abstract 1145: Analysis of circulating tumor cells from castrate resistant prostate cancer patients captured via a microfluidic device using the prostate specific membrane antigen antibody Cancer Research. 70: 1145-1145. DOI: 10.1158/1538-7445.Am10-1145 |
0.408 |
|
| 2010 |
Sung M, Taron M, Rosell R, Giannakakou P. Abstract 1113: The role of BRCA1 in taxane resistance Cancer Research. 70: 1113-1113. DOI: 10.1158/1538-7445.Am10-1113 |
0.446 |
|
| 2009 |
Escuin D, Burke PA, McMahon-Tobin G, Hembrough T, Wang Y, Alcaraz AA, Leandro-García LJ, Rodríguez-Antona C, Snyder JP, Lavallee TM, Giannakakou P. The hematopoietic-specific beta1-tubulin is naturally resistant to 2-methoxyestradiol and protects patients from drug-induced myelosuppression. Cell Cycle (Georgetown, Tex.). 8: 3914-24. PMID 19901556 DOI: 10.4161/Cc.8.23.10105 |
0.396 |
|
| 2009 |
Wang X, Li J, Wang Y, Cho KJ, Kim G, Gjyrezi A, Koenig L, Giannakakou P, Shin HJ, Tighiouart M, Nie S, Chen ZG, Shin DM. HFT-T, a targeting nanoparticle, enhances specific delivery of paclitaxel to folate receptor-positive tumors. Acs Nano. 3: 3165-74. PMID 19761191 DOI: 10.1021/Nn900649V |
0.353 |
|
| 2009 |
Zhou J, Vos CC, Gjyrezi A, Yoshida M, Khuri FR, Tamanoi F, Giannakakou P. The protein farnesyltransferase regulates HDAC6 activity in a microtubule-dependent manner. The Journal of Biological Chemistry. 284: 9648-55. PMID 19228685 DOI: 10.1074/Jbc.M808708200 |
0.433 |
|
| 2008 |
Thomas SL, Zhong D, Zhou W, Malik S, Liotta D, Snyder JP, Hamel E, Giannakakou P. EF24, a novel curcumin analog, disrupts the microtubule cytoskeleton and inhibits HIF-1. Cell Cycle (Georgetown, Tex.). 7: 2409-17. PMID 18682687 DOI: 10.4161/Cc.6410 |
0.412 |
|
| 2008 |
Levy BP, Darshan M, Jeske S, Zhou XK, Tagawa ST, Nanus DM, Giannakakou P. The antitumor activity of taxanes in prostate cancer is mediated through inhibition of AR nuclear accumulation and androgen-dependent signaling Journal of Clinical Oncology. 26: 16005-16005. DOI: 10.1200/Jco.2008.26.15_Suppl.16005 |
0.395 |
|
| 2007 |
Schafer-Hales K, Iaconelli J, Snyder JP, Prussia A, Nettles JH, El-Naggar A, Khuri FR, Giannakakou P, Marcus AI. Farnesyl transferase inhibitors impair chromosomal maintenance in cell lines and human tumors by compromising CENP-E and CENP-F function. Molecular Cancer Therapeutics. 6: 1317-28. PMID 17431110 DOI: 10.1158/1535-7163.Mct-06-0703 |
0.321 |
|
| 2007 |
Ganesh T, Yang C, Norris A, Glass T, Bane S, Ravindra R, Banerjee A, Metaferia B, Thomas SL, Giannakakou P, Alcaraz AA, Lakdawala AS, Snyder JP, Kingston DG. Evaluation of the tubulin-bound paclitaxel conformation: synthesis, biology, and SAR studies of C-4 to C-3' bridged paclitaxel analogues. Journal of Medicinal Chemistry. 50: 713-25. PMID 17263521 DOI: 10.1021/Jm061071X |
0.312 |
|
| 2006 |
Kang SH, Cho HT, Devi S, Zhang Z, Escuin D, Liang Z, Mao H, Brat DJ, Olson JJ, Simons JW, Lavallee TM, Giannakakou P, Van Meir EG, Shim H. Antitumor effect of 2-methoxyestradiol in a rat orthotopic brain tumor model. Cancer Research. 66: 11991-7. PMID 17178898 DOI: 10.1158/0008-5472.Can-06-1320 |
0.364 |
|
| 2006 |
Marcus AI, O'Brate AM, Buey RM, Zhou J, Thomas S, Khuri FR, Andreu JM, Díaz F, Giannakakou P. Farnesyltransferase inhibitors reverse taxane resistance. Cancer Research. 66: 8838-46. PMID 16951201 DOI: 10.1158/0008-5472.Can-06-0699 |
0.446 |
|
| 2005 |
Buey RM, Barasoain I, Jackson E, Meyer A, Giannakakou P, Paterson I, Mooberry S, Andreu JM, Díaz JF. Microtubule interactions with chemically diverse stabilizing agents: thermodynamics of binding to the paclitaxel site predicts cytotoxicity. Chemistry & Biology. 12: 1269-79. PMID 16356844 DOI: 10.1016/J.Chembiol.2005.09.010 |
0.33 |
|
| 2005 |
Wang Y, O'Brate A, Zhou W, Giannakakou P. Resistance to microtubule-stabilizing drugs involves two events: beta-tubulin mutation in one allele followed by loss of the second allele. Cell Cycle (Georgetown, Tex.). 4: 1847-53. PMID 16294009 DOI: 10.4161/Cc.4.12.2264 |
0.323 |
|
| 2005 |
Nicolaou KC, Zak M, Rahimipour S, Estrada AA, Lee SH, O'Brate A, Giannakakou P, Ghadiri MR. Discovery of a biologically active thiostrepton fragment. Journal of the American Chemical Society. 127: 15042-4. PMID 16248640 DOI: 10.1021/Ja0552803 |
0.346 |
|
| 2005 |
Gökmen-Polar Y, Escuin D, Walls CD, Soule SE, Wang Y, Sanders KL, Lavallee TM, Wang M, Guenther BD, Giannakakou P, Sledge GW. beta-Tubulin mutations are associated with resistance to 2-methoxyestradiol in MDA-MB-435 cancer cells. Cancer Research. 65: 9406-14. PMID 16230404 DOI: 10.1158/0008-5472.Can-05-0088 |
0.407 |
|
| 2005 |
Escuin D, Kline ER, Giannakakou P. Both microtubule-stabilizing and microtubule-destabilizing drugs inhibit hypoxia-inducible factor-1alpha accumulation and activity by disrupting microtubule function. Cancer Research. 65: 9021-8. PMID 16204076 DOI: 10.1158/0008-5472.Can-04-4095 |
0.365 |
|
| 2005 |
Edler MC, Buey RM, Gussio R, Marcus AI, Vanderwal CD, Sorensen EJ, Díaz JF, Giannakakou P, Hamel E. Cyclostreptin (FR182877), an antitumor tubulin-polymerizing agent deficient in enhancing tubulin assembly despite its high affinity for the taxoid site. Biochemistry. 44: 11525-38. PMID 16114889 DOI: 10.1021/Bi050660M |
0.365 |
|
| 2005 |
Marcus AI, Zhou J, O'Brate A, Hamel E, Wong J, Nivens M, El-Naggar A, Yao TP, Khuri FR, Giannakakou P. The synergistic combination of the farnesyl transferase inhibitor lonafarnib and paclitaxel enhances tubulin acetylation and requires a functional tubulin deacetylase. Cancer Research. 65: 3883-93. PMID 15867388 DOI: 10.1158/0008-5472.Can-04-3757 |
0.395 |
|
| 2005 |
Zhou J, Giannakakou P. Targeting microtubules for cancer chemotherapy. Current Medicinal Chemistry. Anti-Cancer Agents. 5: 65-71. PMID 15720262 DOI: 10.2174/1568011053352569 |
0.451 |
|
| 2005 |
Marcus AI, Peters U, Thomas SL, Garrett S, Zelnak A, Kapoor TM, Giannakakou P. Mitotic kinesin inhibitors induce mitotic arrest and cell death in Taxol-resistant and -sensitive cancer cells. The Journal of Biological Chemistry. 280: 11569-77. PMID 15653676 DOI: 10.1074/Jbc.M413471200 |
0.437 |
|
| 2004 |
Zhou J, O'brate A, Zelnak A, Giannakakou P. Survivin deregulation in beta-tubulin mutant ovarian cancer cells underlies their compromised mitotic response to taxol. Cancer Research. 64: 8708-14. PMID 15574781 DOI: 10.1158/0008-5472.Can-04-2538 |
0.438 |
|
| 2004 |
Escuin D, Simons JW, Giannakakou P. Exploitation of the HIF axis for cancer therapy. Cancer Biology & Therapy. 3: 608-11. PMID 15197342 DOI: 10.4161/Cbt.3.7.954 |
0.41 |
|
| 2003 |
Nicolaou KC, Sasmal PK, Rassias G, Reddy MV, Altmann KH, Wartmann M, O'Brate A, Giannakakou P. Design, synthesis, and biological properties of highly potent epothilone B analogues Angewandte Chemie - International Edition. 42: 3515-3520. PMID 12900969 DOI: 10.1002/Anie.200351819 |
0.303 |
|
| 2003 |
Mabjeesh NJ, Escuin D, LaVallee TM, Pribluda VS, Swartz GM, Johnson MS, Willard MT, Zhong H, Simons JW, Giannakakou P. 2ME2 inhibits tumor growth and angiogenesis by disrupting microtubules and dysregulating HIF. Cancer Cell. 3: 363-75. PMID 12726862 DOI: 10.1016/S1535-6108(03)00077-1 |
0.39 |
|
| 2002 |
Zhou J, Gupta K, Yao J, Ye K, Panda D, Giannakakou P, Joshi HC. Paclitaxel-resistant human ovarian cancer cells undergo c-Jun NH2-terminal kinase-mediated apoptosis in response to noscapine. The Journal of Biological Chemistry. 277: 39777-85. PMID 12183452 DOI: 10.1074/Jbc.M203927200 |
0.376 |
|
| 2002 |
Giannakakou P, Nakano M, Nicolaou KC, O'Brate A, Yu J, Blagosklonny MV, Greber UF, Fojo T. Enhanced microtubule-dependent trafficking and p53 nuclear accumulation by suppression of microtubule dynamics Proceedings of the National Academy of Sciences of the United States of America. 99: 10855-10860. PMID 12145320 DOI: 10.1073/Pnas.132275599 |
0.345 |
|
| 2001 |
Poruchynsky MS, Giannakakou P, Ward Y, Bulinski JC, Telford WG, Robey RW, Fojo T. Accompanying protein alterations in malignant cells with a microtubule-polymerizing drug-resistance phenotype and a primary resistance mechanism. Biochemical Pharmacology. 62: 1469-80. PMID 11728383 DOI: 10.1016/S0006-2952(01)00804-8 |
0.402 |
|
| 2001 |
Giannakakou P, Robey R, Fojo T, Blagosklonny MV. Low concentrations of paclitaxel induce cell type-dependent p53, p21 and G1/G2 arrest instead of mitotic arrest: Molecular determinants of paclitaxel-induced cytotoxicity Oncogene. 20: 3806-3813. PMID 11439344 DOI: 10.1038/Sj.Onc.1204487 |
0.313 |
|
| 2000 |
Giannakakou P, Poy G, Zhan Z, Knutsen T, Blagosklonny MV, Fojo T. Paclitaxel selects for mutant or pseudo-null p53 in drug resistance associated with tubulin mutations in human cancer. Oncogene. 19: 3078-85. PMID 10871860 DOI: 10.1038/Sj.Onc.1203642 |
0.369 |
|
| 2000 |
Giannakakou P, Gussio R, Nogales E, Downing KH, Zaharevitz D, Bollbuck B, Poy G, Sackett D, Nicolaou KC, Fojo T. A common pharmacophore for epothilone and taxanes: molecular basis for drug resistance conferred by tubulin mutations in human cancer cells. Proceedings of the National Academy of Sciences of the United States of America. 97: 2904-9. PMID 10688884 DOI: 10.1073/Pnas.040546297 |
0.363 |
|
| 2000 |
Giannakakou P, Sackett D, Fojo T. Tubulin/microtubules: still a promising target for new chemotherapeutic agents. Journal of the National Cancer Institute. 92: 182-3. PMID 10655426 DOI: 10.1093/Jnci/92.3.182 |
0.393 |
|
| 1999 |
Gabriele L, Phung J, Fukumoto J, Segal D, Wang IM, Giannakakou P, Giese NA, Ozato K, Morse HC. Regulation of apoptosis in myeloid cells by interferon consensus sequence-binding protein. The Journal of Experimental Medicine. 190: 411-21. PMID 10430629 DOI: 10.1084/Jem.190.3.411 |
0.305 |
|
| 1998 |
Kingston DG, Chaudhary AG, Chordia MD, Gharpure M, Gunatilaka AA, Higgs PI, Rimoldi JM, Samala L, Jagtap PG, Giannakakou P, Jiang YQ, Lin CM, Hamel E, Long BH, Fairchild CR, et al. Synthesis and biological evaluation of 2-acyl analogues of paclitaxel (Taxol). Journal of Medicinal Chemistry. 41: 3715-26. PMID 9733497 DOI: 10.1021/Jm980229D |
0.343 |
|
| 1998 |
Blagosklonny MV, Giannakakou P, Wojtowicz M, Romanova LY, Ain KB, Bates SE, Fojo T. Effects of p53-expressing adenovirus on the chemosensitivity and differentiation of anaplastic thyroid cancer cells. The Journal of Clinical Endocrinology and Metabolism. 83: 2516-22. PMID 9661637 DOI: 10.1210/Jcem.83.7.4984 |
0.315 |
|
| 1998 |
Wang TH, Wang HS, Ichijo H, Giannakakou P, Foster JS, Fojo T, Wimalasena J. Microtubule-interfering agents activate c-Jun N-terminal kinase/stress-activated protein kinase through both Ras and apoptosis signal-regulating kinase pathways. The Journal of Biological Chemistry. 273: 4928-36. PMID 9478937 DOI: 10.1074/Jbc.273.9.4928 |
0.319 |
|
| 1998 |
Giannakakou P, Villalba L, Li H, Poruchynsky M, Fojo T. Combinations of paclitaxel and vinblastine and their effects on tubulin polymerization and cellular cytotoxicity: characterization of a synergistic schedule. International Journal of Cancer. 75: 57-63. PMID 9426691 DOI: 10.1002/(Sici)1097-0215(19980105)75:1<57::Aid-Ijc10>3.0.Co;2-A |
0.375 |
|
| 1997 |
Kowalski RJ, Giannakakou P, Gunasekera SP, Longley RE, Day BW, Hamel E. The microtubule-stabilizing agent discodermolide competitively inhibits the binding of paclitaxel (Taxol) to tubulin polymers, enhances tubulin nucleation reactions more potently than paclitaxel, and inhibits the growth of paclitaxel-resistant cells. Molecular Pharmacology. 52: 613-22. PMID 9380024 DOI: 10.1124/Mol.52.4.613 |
0.391 |
|
| 1997 |
Sackett DL, Giannakakou P, Poruchynsky M, Fojo A. Tubulin from paclitaxel-resistant cells as a probe for novel antimicrotubule agents. Cancer Chemotherapy and Pharmacology. 40: 228-32. PMID 9219506 DOI: 10.1007/S002800050651 |
0.373 |
|
| 1997 |
Giannakakou P, Sackett DL, Kang YK, Zhan Z, Buters JT, Fojo T, Poruchynsky MS. Paclitaxel-resistant human ovarian cancer cells have mutant beta-tubulins that exhibit impaired paclitaxel-driven polymerization. The Journal of Biological Chemistry. 272: 17118-25. PMID 9202030 DOI: 10.1074/Jbc.272.27.17118 |
0.375 |
|
| 1997 |
Nicolaou KC, Winssinger N, Pastor J, Ninkovic S, Sarabia F, He Y, Vourloumis D, Yang Z, Li T, Giannakakou P, Hamel E. Synthesis of epothilones A and B in solid and solution phase. Nature. 387: 268-72. PMID 9153390 DOI: 10.1038/387268A0 |
0.302 |
|
| 1997 |
Kowalski RJ, Giannakakou P, Hamel E. Activities of the microtubule-stabilizing agents epothilones A and B with purified tubulin and in cells resistant to paclitaxel (Taxol(R)). The Journal of Biological Chemistry. 272: 2534-41. PMID 8999970 DOI: 10.1074/Jbc.272.4.2534 |
0.393 |
|
| 1997 |
Tillgada E, Giannakakou P, Karavokyros I, Delitheos A. Effect of calcium channel blockers on the action of various antitumour agents in the yeast Saccharomyces cerevisiae. The Journal of Applied Bacteriology. 81: 481-5. PMID 8939026 DOI: 10.1111/J.1365-2672.1996.Tb03536.X |
0.318 |
|
| Show low-probability matches. |